Healthcare Industry News: Head and Neck Cancer
News Release - July 25, 2018
Addenbrooke's Hospital is First in the UK to Treat Cancer Patients with Accuray Radixact(R) SystemInternationally Renowned Centre in Cambridge, England is First NHS Hospital to Install the Innovative Radiation Therapy System
SUNNYVALE, Calif., July 25, 2018 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Addenbrooke's Hospital clinical team has treated the first cancer patients in the United Kingdom with the innovative Radixact® System. Addenbrooke's Hospital, part of the Cambridge University Hospitals NHS Foundation Trust, purchased one Radixact System through the NHS England radiotherapy equipment upgrade fund, with a second system funded by the Trust. These systems have replaced existing, older TomoTherapy® Systems and will improve the treatment process workflow, enabling the clinical team to efficiently deliver highly precise treatments for a broad range of indications.
Addenbrooke's Hospital is an internationally renowned teaching hospital and designated academic health science centre. The clinical team sees more than 4,000 new patients each year as a regional centre for rarer types of cancer and also as the local hospital for patients living in the Cambridge area.
"Addenbrooke's Hospital was the first NHS hospital to invest in the TomoTherapy Hi·Art® System and is now the first to secure the Radixact System, which supports our strategy to provide quality cancer care using the most advanced technology available," said Kevin Skilton, Operational Head of Radiotherapy, Addenbrooke's Hospital. "We have been extremely pleased with our initial experience using the Radixact System and we look forward to exploring the opportunities the Radixact System may offer us in the treatment of our patients."
Radixact System Benefits
- The Radixact System, the next generation TomoTherapy platform, is capable of treating virtually any radiation therapy indication including breast, lung, prostate, and Head and Neck Cancers, in addition to complex treatments such as total marrow irradiation, on a single mainstream platform
- The system features a more powerful linear accelerator than prior generations, low-dose fan beam 3DCT image guidance and helical delivery technology. These unique features enable clinicians to deliver highly accurate, individualized dose distributions which precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients
- A fully-integrated, simplified adaptive treatment planning solution, PreciseART™ Adaptive Radiation Therapy Software, provides clinicians with a unique midcourse decision-making tool and enables them to adapt radiation delivery to changes in tumor size, shape and location within the patient
- The PreciseRTX™ Retreatment Option helps accelerate and enhance the process of creating new treatment plans for patients who have received previous irradiation
"We are pleased to partner with the Addenbrooke's Hospital team to bring our latest radiation therapy platform to the people of England. Addenbrooke's is leading the way for other NHS hospitals seeking to improve the overall patient experience by providing precise and accurate treatment that is personalized to the needs of each individual, regardless of their stage in the cancer treatment continuum," said Lionel Hadjadjeba, MD, Senior Vice President and Chief Commercial Officer at Accuray.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com .
About Cambridge University Hospitals
Cambridge University Hospitals (CUH) is one of the largest and best known hospitals in the UK, delivering high-quality patient care through Addenbrooke's and the Rosie Hospitals. CUH is a leading national centre for specialist treatment for rare or complex conditions and a university teaching hospital with a worldwide reputation.
CUH is a key partner in Cambridge University Health Partners (CUHP), one of only six academic health science centres in the UK, and is at the heart of the development of the Cambridge Biomedical Campus (CBC), which brings together on one site world-class biomedical research, patient care and education. As part of the Campus development, Papworth Hospital is creating a bespoke, purpose-built hospital, and AstraZeneca is building a new global R&D centre and corporate headquarters. The Campus is one of the government's National Institute for Health Research (NIHR) comprehensive biomedical research centres.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, and patient experiences and outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to develop new products or enhance existing products to meet customers' needs, the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2017, the company's quarterly report on Form 10-Q, filed with the SEC on May 2, 2018 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Unveils VOLO(TM) Ultra, the Latest Innovation for the Radixact(R) System, at ASTRO 2021
C-RAD and Accuray Sign Agreement to Enhance Radixact(R) System Breast Cancer Treatment Capabilities
French Hospital Network Unicancer Acquires Multiple Accuray Radixact(R) Systems with the ClearRT(TM) Helical Fan-Beam kVCT Imaging and Synchrony(R) Technologies